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Local, multimodal intralesional 
therapy renders distant brain 
metastases susceptible to PD‑L1 
blockade in a preclinical model 
of triple‑negative breast cancer
Toshihiro Yokoi1,2,7, Takaaki Oba1,3,7, Ryutaro Kajihara1, Scott I. Abrams4 & Fumito Ito1,4,5,6*
Despite recent progress in therapeutic strategies, prognosis of metastatic triple‑negative breast 
cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor‑
residing conventional type‑1 dendritic cells (cDC1s) is critical for the generation of  CD8+ T cells that 
mediate the regression of mammary tumors and potentiate anti‑PD‑1/PD‑L1 therapeutic efficacy. 
However, it remains unknown whether this strategy is effective against metastatic TNBC, which 
is poorly responsive to immunotherapy. Here, using a mouse model of TNBC, we established 
orthotopic mammary tumors and brain metastases, and treated mammary tumors with in situ 
immunomodulation (ISIM) consisting of intratumoral injections of Flt3L to mobilize cDC1s, local 
irradiation to induce immunogenic tumor cell death, and TLR3/CD40 stimulation to activate cDC1s. 
ISIM treatment of the mammary tumor increased circulating T cells with effector phenotypes, and 
infiltration of  CD8+ T cells into the metastatic brain lesions, resulting in delayed progression of brain 
metastases and improved survival. Furthermore, although anti‑PD‑L1 therapy alone was ineffective 
against brain metastases, ISIM overcame resistance to anti‑PD‑L1 therapy, which rendered these 
tumor‑bearing mice responsive to anti‑PD‑L1 therapy and further improved survival. Collectively, 
these results illustrate the therapeutic potential of multimodal intralesional therapy for patients with 
unresectable and metastatic TNBC.
Triple-negative breast cancer (TNBC), characterized by the lack of estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (HER2/neu), is an aggressive subtype of breast cancer with 
limited treatment  options1. Women with TNBC have a higher rate of early distant relapse compared to those 
with other subtypes of breast cancer, and thus is associated with poor clinical outcomes despite having an initial 
good response to  chemotherapy1. Compared to other types of breast cancer, TNBC is more likely to metastasize 
to visceral sites, particularly to the lungs and  brain1. Prognosis of patients with TNBC brain metastases is almost 
uniformly poor, with a median survival of 4.9 months after the development of brain  metastases2,3. Therefore, 
new treatment strategies for TNBC brain metastases are an unmet clinical need.
Notably, TNBC exhibits a higher level of PD-L1 expression associated with the presence of tumor-infiltrating 
lymphocytes (TILs), and a higher degree of mutational burden compared with other subtypes of breast  cancer4–8, 
suggesting that TNBC might be more immunogenic, and thus can be an attractive target of immunotherapy such 
as PD-1/PD-L1 blockade therapy. Indeed, the efficacy of anti-PD-L1 blockade (atezolizumab) combined with 
nab-paclitaxel has recently been demonstrated in TNBC in the advanced or metastatic  setting9; progression-free 
survival was significantly longer in the atezolizumab–nab-paclitaxel group than in the placebo–nab-paclitaxel 
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group (median, 7.2 months vs. 5.5 months; 95% confidence interval 0.69 to 0.92; P = 0.002). However, given that 
durable responses in patients treated with anti-PD-1/PD-L1 therapy and chemotherapy are rare, there is both 
scientific and clinical justification to explore novel therapeutic strategies to further improve patient  outcomes9.
The tumor immune microenvironment (TME) plays a key role in clinical outcomes of patients with many 
cancer types, including TNBC. The frequency of TILs substantially influences the likelihood of achieving a patho-
logic complete response (pCR) to neoadjuvant chemotherapy and improve patient  prognosis10,11. Furthermore, 
the presence of TILs in TNBC also correlates with response to immunotherapy, which is associated with a high 
level of PD-L1  expression12,13. Therefore, increasing  CD8+ TILs are likely to improve response to immunotherapy 
and/or chemo-immunotherapy.
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells (APCs) that play critical roles 
in linking innate and adaptive  immunity14,15. Among various subsets of DCs, Batf3-dependent conventional type 
1 dendritic cells (cDC1s; migratory  CD103+ and lymphoid CD8α+ DCs in mice, and  CD141+ DCs in humans) 
have enhanced abilities to phagocytose dead cells and transport tumor-associated antigens (TAAs) to tumor-
draining lymph nodes (TdLN), where they cross-present TAAs to  CD8+ T  cells16. Evidence revealed that cDC1s 
in the TME play pivotal roles in the priming and expansion of tumor-specific  CD8+ T  cells17–22, promoting their 
infiltration into the  TME23, and thus enhancing the efficacy of anti-PD-1  therapy24–26. Although cDC1s are rare 
populations in the TME, they can be induced by in situ or systemic administration of Fms-like tyrosine kinase 
3 receptor ligand (Flt3L)17,18,24–29.
In situ immunomodulation (ISIM) is a multimodal intralesional therapy comprised of in situ delivery of Flt3L, 
radiotherapy, and dual CD40/TLR3  stimulation29. Using multiple orthotopic murine tumor models of poorly T 
cell-inflamed tumors including TNBC, we have demonstrated that ISIM: mobilizes cDC1s to the TME; induces 
maturation of cDC1s; facilitates trafficking of cDC1 carrying TAAs to the TdLN; elicits de novo adaptive T cell 
immunity; triggers rapid regression of primary tumors, as well as non-irradiated contralateral tumors; renders 
non-T cell-inflamed tumors responsive to anti-PD-L1 therapy; reshapes clonally expanding T-cell receptor (TCR) 
repertoires in tumors; overcomes acquired resistance to anti-PD-L1 therapy, resulting in eradication of tumors; 
and develops tumor-specific systemic immunological  memory29,30. However, whether ISIM develops enhanced 
systemic antitumor immunity and controls distant brain metastases remains unknown, which has significant 
translational implications for those patients with few, if any, therapeutic options.
In this study, using an orthotopic mouse model of TNBC brain metastases, we hypothesized that ISIM-
induced local immunity led to systemic antitumor activity that delayed the progression of established brain 
metastases and improved survival, alone or in combination with anti-PD-L1 therapy. The results from this study 
support our central hypothesis and reveal the translational potential of ISIM for patients with unresectable or 
metastatic TNBC.
Methods
Mice. Female C57BL/6 mice were purchased from the Jackson Laboratories. All mice were age matched of 
7–9 weeks old at the beginning of each experiment. Mice were maintained under specific pathogen-free condi-
tions and housed in the Laboratory Animal Resources facility. All studies were conducted in accordance with 
ARRIVE guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) at the Roswell 
Park Comprehensive Cancer Center.
Cell lines. The AT-3 tumor cell line was established from a primary mammary gland carcinoma of the 
PyMT-MMTV transgenic mice on a B6 strain and was maintained as  described31. AT-3 cells were cultured in 
Gibco Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum (FBS) (Sigma), 1% non-
essential amino acid (NEAA) (Gibco), 2 mM l-glutamine (Gibco), 0.5% penicillin/streptomycin (Gibco), and 
55 μM 2-mercaptoethanol (Gibco). AT-3 tumor cells expressing luciferase (AT-3-luc) were generated with infec-
tion of lentiviruses encoding luciferase (pLenti PGK V5-LUC Neo, Addgene plasmid #21471). These cell lines 
were authenticated by morphology, phenotype, and growth, and routinely screened for Mycoplasma, and were 
maintained at 37 °C in a humidified 7% CO2 atmosphere.
Tumor inoculation. AT-3 (5 ×  105) tumor cells were orthotopically implanted into the fourth mammary 
gland of female mice under anesthesia with isoflurane. Brain metastases were established by intra-cardiac injec-
tion of AT-3-luc (1 ×  106) tumor cells through the fourth intra-costal space under anesthesia with isoflurane as 
previously  described32,33.
In situ immunomodulation (ISIM). Tumor-bearing mice were treated with hFlt3L (10 μg/dose; Celldex 
Therapeutics, Inc.) in 30 μL PBS or control PBS intratumorally daily for 5 days. Local irradiation of orthotopic 
mammary tumors was  described29. In brief, the mice were anesthetized with isoflurane and positioned under 
a 2 mm thick lead shield with small apertures limiting exposure to the tumors. The tumor received 9 Gy local 
irradiation with an orthovoltage X-ray machine (Philips RT250, Philips Medical Systems) at 200 kV using a 
1 × 2 cm cone. One day after radiotherapy, mice were treated with injection of high molecular weight poly(I:C) 
(50 μg/dose; InvivoGen) and agonistic anti-CD40 Ab (50 μg/dose; clone FGK4.5, BioXcell) at the peritumoral 
site subcutaneously. For the second and subsequent ISIM treatments in a serial ISIM protocol, PBS or Flt3L 
was injected starting 1 day after TLR3/CD40 stimulation for 5 days. Radiotherapy and TLR3/CD40 agonists 
were given 1 and 2 days after completion of Flt3L or PBS injection, respectively. Mammary tumor growth was 
measured 3–4 times a week, and the volumes were calculated by determining the length of short (l) and long (L) 
diameters (volume = l2 × L/2). Experimental endpoints were reached when mice became moribund and showed 
neurological focal signs of cachexia, lateral recumbency, lack of response to noxious stimuli.
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Anti‑PD‑L1 therapy. Anti-PD-L1 antibody (Ab) (clone 10F.9G2, BioXcell) or isotype rat IgG2b (clone 
LTF-2, BioXcell) was injected intraperitoneally (i.p.) every third day at a dose of 200 μg/mouse29,30,34–36 starting 
on the day radiotherapy was performed.
In vivo bioluminescence imaging. To monitor brain metastases of established AT-3-luc tumors, mice 
were injected with d-luciferin (1.5 mg/20 g body weight) intraperitoneally, and images were obtained by in vivo 
bioluminescence imaging (IVIS Spectrum imager) was used as  described29.
Flow cytometry. Single cell suspensions of spleens were blocked with anti-mouse CD16/32 (BioLegend) 
and surface stained with the indicated markers, and evaluated by flow cytometric analysis as  described18,29,35–37. 
The following Abs were used; anti-CD45 (clone 30-F11, Invitrogen), anti-PD-1 (clone 29F.1A12, BioLegend), 
anti-CX3CR1 (clone SA011F11, BioLegend), anti-KLRG1 (clone 2F1/KLRG1, BioLegend), anti-CD4 (clone 
GK1.5, BioLegend), anti-CD8α (clone 53-6.7, BD Biosciences), and anti-CD3 (clone 145-2C11, BioLegend). 
LIVE/DEAD Fixable Near-IR Dead Cell Stain kit (Thermo Fisher Scientific)-stained cells were excluded from 
the analysis. Samples were acquired by Fortessa (BD Biosciences) cytometers, and analyzed with FlowJo software 
(Treestar).
Immunohistochemistry staining. The frequency of Immunohistochemistry (IHC) staining was per-
formed as  described29. To identify  CD8+ cells in brain, anti-CD8α (1:400, Clone D4W2Z, Cell Signaling Technol-
ogy) was used. Images were obtained with a Zeiss Axio Imager Z1. The number of cells showing CD8 positivity 
in each individual high-power field (HPF) (× 200) was quantified across five fields or more of nonsequential 
cryosections 9 mm in thickness.
Statistical analysis. Statistical analysis was performed using two-tailed Student’s t-test for comparisons 
between two groups, one-way ANOVA with Tukey’s multiple comparisons for comparisons of more than two 
groups, or the Mantel-Cox method (log-rank test) for survival analysis using GraphPad Prism 8.02 (GraphPad 
Software)29,30. P < 0.05 was considered statistically significant.
Ethics approval. All animal studies were reviewed and approved by the Roswell Park institutional animal 
care and use program and facilities (protocol #1316M and 1356M). All aspects of animal research and hus-
bandry were conducted in accordance with the federal Animal Welfare Act and the NIH Guide for the Care and 
Use of Laboratory Animals. Further, all methods are reported in accordance with ARRIVE guidelines (https:// 
arriv eguid elines. org).
Results
In situ immunomodulation (ISIM) of mammary tumors with Flt3L, radiotherapy and TLR3/
CD40 agonists controls established brain metastases and improves survival. To test systemic 
antitumor efficacy of ISIM against brain metastatic TNBC, we utilized an established brain metastasis model by 
intra-cardiac injection of AT-3-luc  tumors32.
AT-3 tumor cells were orthotopically implanted into the fourth mammary gland, and AT-3-luc tumor cells 
were injected into the left ventricle under anesthesia (Supplementary Fig. S1a). Establishment and progression 
of brain metastases were confirmed and monitored by IVIS. (Supplementary Fig. S1b). Mammary tumors were 
treated with ISIM comprised of intratumoral injections of Flt3L to recruit cDC1s into the TME, radiotherapy to 
induce immunogenic tumor cell death and maturation of DCs, and in situ administration of TLR3/CD40 agonists 
to facilitate trafficking of Ag-loaded cDC1s to TdLN and the subsequent priming and expansion of tumor-specific 
 CD8+ T  cells29 (Fig. 1a). Control mice received intratumoral injections of PBS. ISIM mediated effective regression 
of orthotopic AT-3 mammary tumors with substantially delayed tumor growth (Fig. 1b). Untreated mice showed 
progressive growth of brain metastases (Fig. 1c). In contrast, ISIM treatment of orthotopic mammary tumors 
controlled the growth of distant brain metastases and substantially improved survival (Fig. 1d).
ISIM facilitates activation and effector differentiation of  CD4+ and  CD8+ T cells. To gain insights 
into the potential systemic antitumor efficacy of ISIM treatment of mice bearing orthotopic mammary tumors 
with brain metastasis, we evaluated the phenotype of  CD4+ and  CD8+ T cells in the spleens of untreated or ISIM-
treated mice by flow cytometry (Fig. 2a). Markedly increased frequencies of  CD4+ and  CD8+ T cells expressing 
markers of activation (PD-1, 4-1BB), differentiation (CX3CR1), and effector phenotype (KLRG1) was observed 
in ISIM-treated mice compared to untreated mice (Fig. 2b), suggesting effective activation of adaptive T cell 
immunity in mice bearing orthotopic mammary tumors with brain metastatic disease in response to ISIM.
ISIM promotes  CD8+ T cell infiltration into intracranial lesions. Next, we investigated whether ISIM 
treatment of mammary tumors could facilitate the infiltration of  CD8+ T cells into the distant brain metastases. 
To this end, we treated mice bearing orthotopic mammary tumors and established brain metastases with ISIM 
and collected brain tissue 7 days after completion of the regimen. Immunohistochemical (IHC) analysis revealed 
sparse  CD8+ T cells in intracranial metastatic lesions in untreated mice (Fig. 3). In contrast, the frequency of 
 CD8+ T cells in brain metastases was substantially increased in ISIM-treated mice compared to untreated mice 
(Fig. 3). These results suggest that ISIM treatment of primary tumors triggers systemic antitumor immunity and 
generates  CD8+ T cells that could pass through the blood brain barrier, and traffic to metastatic sites, causing 
immune remodeling and regression of untreated intracranial brain tumors.
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Serial ISIM treatment of mammary tumors and anti‑PD‑L1 therapy exhibit synergistic antitu‑
mor efficacy and improves survival in mice with established brain metastases. We have recently 
reported that ISIM treatment with Flt3L, radiotherapy and TLR3/CD40 agonists could reshape intratumoral T 
Figure 1.  ISIM treatment of mammary tumors with Flt3L, radiotherapy and TLR3/CD40 agonists controls 
established brain metastases and improves survival. (a) Treatment protocol of ISIM in mice bearing established 
orthotopic mammary and brain metastatic tumors. Illustrations here were created with www. Biore nder. com. 
(b) Tumor volume curves (mean) and waterfall plots of AT-3 mammary tumors in mice bearing AT-3-luc brain 
metastatic tumors. Orthotopic mammary tumors were treated with PBS (NT) or ISIM. Waterfall plots show 
maximal change of tumor volume at the day when TLR3/CD40 agonists were administered. (n = 8–9 per group) 
Hazard Ratio (HR) 3.728, confidential interval (CI) 1.128–12.32. (c,d) Representative bioluminescent imaging 
(c) of AT-3-luc brain metastases and survival curves (d) in mice receiving different treatments against mammary 
AT-3 tumors, as indicated. (n = 8–9 per group). *P < 0.05, ***P < 0.001, two-tailed unpaired Student t-test (b), or 
log-rank (Mantel-Cox) test (d). Mean ± SEM. Data shown are representative of two independent experiments.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:21992  | https://doi.org/10.1038/s41598-021-01455-4
www.nature.com/scientificreports/
cell type, density, and repertoires, convert poorly T cell-inflamed tumors, and overcome primary and acquired 
resistance to anti-PD-L1  therapy29. However, it remained unknown whether anti-PD-L1 therapy potentiates the 
abscopal effect of serial ISIM treatment against brain metastases. To this end, we treated mice bearing estab-
lished orthotopic mammary tumors and brain metastases with serial ISIM and anti-PD-L1 therapy. Treatment 
with anti-PD-L1 therapy alone did not improve control of brain metastases or survival compared to untreated 
mice (Fig. 4a,b). In contrast, serial ISIM treatment significantly improved survival and further synergized with 
anti-PD-L1 therapy. Collectively, these findings suggest that in situ induction and activation of cDC1s in the 
mammary tumors generates potent systemic antitumor immunity, delays the formation of established distant 
brain metastases, overcomes resistance to anti-PD-L1 therapy, renders them responsive to anti-PD-L1 therapy 
and improves survival.
Discussion
Breast cancer is considered immunologically quiescent, representing a challenge for immunotherapy. Although 
TNBC has a higher rate of PD-L1 expression associated with the presence of tumor-infiltrating lymphocytes, 
and a higher degree of mutational burden compared with other subtypes of breast  cancer4–8, the overall response 
rate to PD-1/PD-L1 blockade therapy is still  low13. Due to limited treatment options and a lack of proven effec-
tive targeted therapies, there is a critical need for the development of new therapeutic approaches for patients 
with TNBC. The work described herein demonstrates that in situ induction and activation of cDC1s in poorly 
T cell-inflamed tumors facilitates the infiltration of  CD8+ T cells in distant non-irradiated CNS lesions, delays 
the progression of established TNBC brain metastases, renders them responsive to anti-PD-L1 therapy and 
improves survival.
Our approach to improve anti-PD-1/PD-L1 blockade therapy focuses on converting non- or poorly T cell-
inflamed tumors to T-cell inflamed ones. Our findings of increased  CD8+ T cells and delayed progression of 
Figure 2.  ISIM facilitates activation and effector differentiation of  CD4+ and  CD8+ T cells. (a,b) AT-3 and 
AT-3-luc tumor cells were inoculated into the fourth mammary gland and left ventricle, respectively. Orthotopic 
mammary tumors were treated with PBS (NT) or ISIM and spleens were collected 7 days after intratumoral 
administration of TLR3/CD40 agonists. (a) Gating strategy for phenotypic analysis of  CD4+ and  CD8+ T cells in 
the spleen. (b) Representative flow cytometric plots showing 4-1BB, PD-1, CX3CR1 and KLRG1 expression in 
 CD4+ T cells (left) and  CD8+ T cells (right) in spleen. Numbers, percent positive cells. Data panels show mean 
percentage of positive cells in  CD4+ and  CD8+ T cells (n = 5 per group). **P < 0.01, ***P < 0.001, ****P < 0.0001, 
two-tailed unpaired Student t-test. Mean ± SD. Data shown are representative of two independent experiments.
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:21992  | https://doi.org/10.1038/s41598-021-01455-4
www.nature.com/scientificreports/
established TNBC brain metastases by ISIM treatment of mammary tumors are in line with our recent data in 
mouse models bearing bilateral mammary  tumors29, and further demonstrated that this can occur in metastatic 
lesions that cross the blood–brain-barrier. Evidence suggests that T cells within the TME of the CNS are respon-
sible for therapeutic efficacy of anti-PD-1  therapy38. High density of TILs is associated with better prognosis 
not only in various solid malignant tumors but also in brain  metastases39, suggesting that ISIM with or without 
anti-PD-1/PD-L1 therapy may represent a novel approach that could potentially improve clinical outcome in at 
least some patients with TNBC brain metastases.
Local irradiation increases the levels of tumor-residing DCs, enhances the mobilization of these cells into 
the TdLN, augments their maturation, and increases their ability to cross-present antigens (Ags) to prime T 
 cells40–45. However, this process is often hindered by the immunosuppressive TME, and the abscopal effect is 
only rarely seen in patients even in the presence of immune checkpoint  inhibitors46–51. Our data indicate that 
in situ induction and activation of cDC1s augments immunogenicity of radiotherapy against untreated poorly 
T cell-inflamed tumors and generates abscopal effects in brain metastases. Optimal dose and fractionation of 
radiotherapy to the primary tumor after induction of cDC1s; however, remain unknown. Too small of a dose 
might not cause significant immunogenic cell death and the release of tumor Ags, but too much of a dose or too 
many cycles of irradiation might alter the viability of Flt3L-induced cDC1s, or negatively impact their ability to 
traffic to the TdLN and/or capacity to cross-present TAAs. Therefore, more work is warranted to determine the 
optimal radiotherapy regimen to maximize the engagement of cDC1s to enhance ISIM-induced abscopal effects. 
ISIM has some features that might be applicable for the treatment of unresectable and metastatic TNBC. First, 
intralesional therapy allows for achieving higher concentrations of immunomodulatory agents in the TME, while 
minimizing systemic toxicities. Second, this local combinatorial treatment may allow for the use of concurrent 
systemic therapy, such as chemotherapy plus anti-PD-1/PD-L1 therapy, and potentiate their antitumor efficacy 
because of ISIM-mediated increases in  CD8+ T cell infiltration in mammary tumors, but more importantly 
distant metastatic lesions. Third, ISIM could cause robust regression of distant untreated  tumors29, which might 
be important for patients with visceral metastases that are extremely challenging to control or eradicate. Several 
potential limitations exist in the ISIM treatment in clinical setting. First, the primary tumors must be palpable 
or accessible under image guidance for repetitive injections. Second, antitumor efficacy of ISIM depends on de 
novo adaptive T-cell immune responses elicited at secondary lymphoid  organs29. Therefore, therapeutic efficacy 
of ISIM for patients with history of regional lymph node surgery remains to be determined. Third, although rapid 
regression of the treated and distant untreated tumors was observed in preclinical  models29, it remains unclear 
whether this is the case against brain metastases when immediate intervention is required. Current therapy 
for brain metastases of breast cancer involves radiotherapy and surgery. Compelling evidence has shown that 
systemic Flt3L injections could induce tumor-residing  cDC1s24,25,27,28 and synergize with radiotherapy and sys-
temic anti-CD40  Ab27. Therefore, it is possible that irradiating brain metastases may have additive or synergistic 
antitumor efficacy with ISIM treatment of mammary tumors with or without anti-PD-L1 therapy. Although the 
scope of our studies is limited to assess the abscopal effect of ISIM, future investigations are necessary to evaluate 
the potential synergy of ISIM and radiotherapy to brain metastases.
Approaches that take advantage of the induction and activation of tumor-residing cDC1s has gained consid-
erable attention  recently17,18,24–29. In situ vaccination with Flt3L, radiotherapy and Poly-ICLC mediates regres-
sion of distant lesions in patients with  lymphoma26, and a clinical trial with anti-PD-1 therapy is under way for 
Figure 3.  ISIM promotes  CD8+ T cell infiltration into intracranial lesions. AT-3 and AT-3-luc tumor cells 
were inoculated into the fourth mammary gland and left ventricle, respectively. Orthotopic mammary 
tumors were treated with PBS (NT) or ISIM, and brain tumor tissues were collected 7 days after intratumoral 
administration of TLR3/CD40 agonists. Representative images of immunohistochemistry for  CD8+ T cells in 
brain tumor tissue. Images in low-power field (LPF) (upper) and high-power field (HPF) (lower) are shown. 
Scale bars, 100 µm. A data panel shows mean numbers of  CD8+ T cells per each HPF within 5 different areas 
for each tumor (n = 4–5 per group). **P < 0.01, two-tailed unpaired Student t-test. Mean ± SD. Data shown are 
representative of two independent experiments.
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patients including breast cancer (NCT03789097). A clinical trial involving subcutaneous injections of Flt3L and 
radiotherapy in combination with anti-PD-1 therapy for patients with breast cancer is ongoing (NCT03804944). 
Systemic administration of Flt3L and agonistic anti-CD40 Ab are also being tested for patients with pancre-
atic cancer (NCT04536077). Although we have shown delayed progression of established brain metastases in 
response to ISIM treatment of mammary tumors, the safety and feasibility of ISIM still needs to be evaluated in 
a clinical setting (NCT04616248) before its use in patients with synchronous mammary tumors with and brain 
metastatic lesions.
In summary, we evaluated the systemic antitumor efficacy against brain metastases by combinatorial intral-
esional multimodal therapy using a preclinical model of poorly T cell-inflamed TNBC. We also demonstrated 
that therapeutic responses could be further potentiated by the addition of anti-PD-L1 therapy. Collectively, these 
data have important implications for the design and use of therapeutic strategies that activate and engage cDC1-
CD8+ T cell interactions to target distant metastases, thus providing the rationale for ISIM-based immunotherapy 
in patients with metastatic TNBC.
Data availability
All data generated and analyzed are available from the corresponding author upon reasonable request.
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